Treatment with mTOR inhibitors restored the IL-17/TGF-β ratio in the asthmatic mice, suggesting that inhibiting mTOR pathway activation reversed the loss of Th17/Treg balance during asthma onset. This evidence concerns the gene TGFB1 and asthma.